MABVAX THERAPEUTICS HOLDINGS, INC.
MBVX evidence brief
What we can confirm
- BioSniper Score:
- 4.3 / 10
- Lead Asset:
- mvt-1075 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for MBVX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
mvt-1075 (Phase 1)
Next Catalyst
—
Tracking 2 pipeline candidates for MABVAX THERAPEUTICS HOLDINGS, INC..
Run MABVAX THERAPEUTICS HOLDINGS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MABVAX THERAPEUTICS HOLDINGS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Frequently asked questions
What is MABVAX THERAPEUTICS HOLDINGS, INC.'s lead drug candidate?
MABVAX THERAPEUTICS HOLDINGS, INC.'s most advanced tracked candidate is mvt-1075 (Phase 1) for Locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies.
What therapeutic areas does MABVAX THERAPEUTICS HOLDINGS, INC. focus on?
MABVAX THERAPEUTICS HOLDINGS, INC. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.